GlassScriptPhysician profile
Nathan A Davis
NPI 1841443231
$8,667.84
in general payments reported to CMS, 2019-2025
32 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $203 · 2021: $390 · 2022: $1,414 · 2023: $1,791 · 2024: $2,136 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,224 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,223.90 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,611.61 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,212.82 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $988.98 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $836.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $684.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $325.19 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $302.50 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Ucb, INC. | $182.23 | 2019-2023 | Cimzia, Bimzelx |
| Incyte Corporation | $174.32 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $163.14 | 2019-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $151.99 | 2019-2021 | |
| Lilly USA, LLC | $137.25 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Genentech USA, INC. | $124.38 | 2019-2022 | |
| Amgen INC. | $118.69 | 2019-2025 | Otezla, Otezla |
| Comsort, INC | $100.00 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $95.57 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $66.76 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $58.04 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $57.75 | 2019 | |
| Dermavant Sciences, INC. | $36.97 | 2023-2024 | Vtama |
| Dermira, INC. | $33.76 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.34 | 2019 | |
| Mylan Pharmaceuticals INC. | $27.02 | 2019 | |
| Celgene Corporation | $26.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.42 | 2024 | Spevigo |
| Biofrontera INC. | $16.52 | 2019 | |
| Springworks Therapeutics, INC. | $16.34 | 2024 | Ogsiveo |
| Dusa Pharmaceuticals, INC. | $15.48 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.80 | 2019 | |
| Allergan, INC. | $12.03 | 2019 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 | |
| Organon LLC | $10.61 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.